Prezcobix Ped Tablet, For Suspension
Product Images NDC 59676-577

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Prezcobix Ped (NDC 59676-577). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Products, Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Prezcobix 01)

Chemical structure of darunavir ethanolate, one of the active ingredients in PREZCOBIX PED tablets for suspension. The diagram depicts the molecular arrangement including functional groups and ethanol (C2H5OH) association.*

FDA Label Image

Chemical Structure (Prezcobix 02)

Chemical structure diagram of darunavir ethanolate, one of the active ingredients in PREZCOBIX PED tablets for suspension, showing the molecular arrangement of atoms and bonds.*

FDA Label Image

Figure 1 (Prezcobix 03)

A comparative bar chart showing geometric mean ratios (GMR) with 90% confidence intervals for Darunavir/cobicistat once daily during the second and third trimesters of pregnancy. The chart presents pharmacokinetic parameters including total and unbound AUC and Cmin values with corresponding numerical GMR data for these periods.*

FDA Label Image

Figure 1a (Prezcobix 04)

Label for PREZCOBIX PED tablets containing 800 mg darunavir ethanolate and 150 mg cobicistat, oral tablet for suspension. It shows the proprietary name PREZCOBIX, the active ingredients darunavir and cobicistat, dosage strength 800 mg/150 mg, and a quantity of 30 tablets. The label includes manufacturer information for Janssen Products, LP, along with storage instructions and warnings.*

FDA Label Image

Image (Prezcobix 05)

An instructional illustration showing a hand opening a bottle by pressing down and turning the cap, labeled with numbers 1 and 2 to indicate the sequence of actions.*

FDA Label Image

Image (Prezcobix 06)

An instructional illustration showing a hand dropping a tablet into a cup, representing the preparation or administration of an oral tablet for suspension product, such as Prezcobix Ped (darunavir ethanolate and cobicistat).*

FDA Label Image

Image (Prezcobix 07)

An instructional illustration showing a hand gripping the cap of a bottle with an arrow indicating the direction to twist, demonstrating how to open the bottle cap. This image is likely related to the preparation or use of the Prezcobix PED oral suspension tablets.*

FDA Label Image

Image (Prezcobix 08)

An instructional illustration showing a hand holding a spoon with liquid being poured into a glass containing a tablet at the bottom. This depicts preparation of a suspension dosage form, likely for oral administration of PREZCOBIX PED tablets for suspension.*

FDA Label Image

Image (Prezcobix 09)

An instructional illustration showing a hand stirring a suspension in a clear cup using a spoon. The motion is indicated by arrows, demonstrating the mixing action typically used to prepare an oral suspension medication, such as a tablet for suspension form.*

FDA Label Image

Prezcobix 800 mg Pdp (Prezcobix 10)

PREZCOBIX PED tablets containing darunavir ethanolate and cobicistat, with strength 800 mg/150 mg. The label shows the NDC 59676-575-30 and indicates a package size of 30 tablets. The manufacturer is Janssen Products, LP, a division of Johnson & Johnson. The label includes dosage, storage instructions, and safety warnings. The product is for oral use as tablets for suspension.*

FDA Label Image

Principal Display Panel (675 mg/150 mg Tablet Bottle Carton)

Packaging label for PREZCOBIX tablets, containing darunavir and cobicistat 675 mg/150 mg per tablet. The label shows the product name, active ingredients, dosage strength, and tablet form. Manufactured by Janssen Products, LP, the carton includes a 30-tablet count and safety information, including storage instructions and child-resistant packaging. The Johnson & Johnson logo is present on the label.*

FDA Label Image

Principal Display Panel (600 mg/90 mg Tablet Bottle Carton)

The image shows a carton label for PREZCOBIX PED tablets for oral suspension containing darunavir and cobicistat at 600 mg/90 mg strength. The packaging indicates the product is manufactured by Janssen Products, LP, Horsham, PA, and contains 30 tablets. Instructions advise dispersing the tablet in drinking water without crushing or chewing. Dosage and storage information is provided, and the label includes the Johnson & Johnson logo and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.